Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol/glycopyrrolate - AstraZeneca

Next Previous
X
Search
Drug Profile

Formoterol/glycopyrrolate - AstraZeneca

Alternative Names: Bevespi; BEVESPI AEROSPHERE; Formoterol fumarate/glycopyrronium; GFF MDI; Glycopyrrolate/formoterol; PT-003; PT001/PT005; PT003-GFF; PT005/PT001

Latest Information Update: 05 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Feb 2024 AstraZeneca plans a phase III THARROS trial for Chronic obstructive pulmonary disease in the US, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Malaysia, Mexico, Norway, Peru, Philippines, Poland, Romania, Serbia, Spain, Sweden, Taiwan, Thailand, Turkey and the United Kingdom (Inhalation) in February 2024 (NCT06283966)
  • 21 Feb 2024 Phase-III clinical trials in Chronic obstructive pulmonary disease in USA, Canada (Inhalation) (NCT06283966)
  • 29 Nov 2022 No development reported - Phase-III for Chronic obstructive pulmonary disease in Russia (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top